Avenue therapeutics, inc. (ATXI)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities:
Net loss

-

-

-

-

-

-

-

-

-21,974

-12,258

0

0

0

-

-

-

-

Net loss

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation

1,303

1,839

2,079

2,152

1,938

1,537

1,377

1,251

949

604

275

34

24

28

0

0

0

Change in fair value of convertible notes payable

-

-

-

-

-

-

-

-

-

99

99

99

-85

0

0

0

0

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

451

531

550

185

188

0

0

0

Debt discount amortization

-

-

-

-

-

-

-

-

-

174

205

131

127

123

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-132

18

-383

-335

-56

-236

333

474

310

388

0

0

0

-

-

-

-

Accounts payable and accrued expenses

-8,524

-2,760

-196

-2,505

3,562

1,125

184

3,408

4,885

2,231

1,518

266

569

15

0

0

0

Accounts payable and accrued expenses - related party

47

-473

-355

-140

-81

434

295

18

231

337

604

884

843

829

0

0

0

Interest payable

-

-

-

-

-

-

-

-

-

-57

0

56

5

57

0

0

0

Accrued interest - related party

-

-

-

-

-

-

-

-

-

-46

14

184

210

181

0

0

0

Net cash used in operating activities

-21,862

-26,259

-22,501

-24,923

-16,965

-18,216

-21,246

-18,989

-13,587

-6,802

0

0

0

-

-

-

-

Cash flows from investing activities:
Milestone payment for research and development licenses

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturity of Short-term investments (certificates of deposits)

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Maturity of Short-term investments (certificates of deposit)

-

-

-

-

-

-10,000

0

0

0

-

-

-

-

-

-

-

-

Net cash used in investing activities

0

-

-

-

-

10,000

10,000

0

0

-10,000

0

0

0

-

-

-

-

Cash flows from financing activities:
Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Issuance of common shares

-

35,000

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

Offering costs

-

2,667

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from notes payable - related party

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Net cash provided by financing activities

-

32,333

0

0

0

-

-

-

28,550

28,387

0

0

0

-

-

-

-

Net change in cash

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from notes payable - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net change in cash

-

-

-

-

-

-

-

-

14,963

11,585

16,020

34,651

-12

183

0

0

0

Cash paid for interest

-

-

-

-

-

-

-

-

-

303

0

0

0

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Non-cash financing activities:
Unpaid offering costs

-

833

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid deferred financing costs

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-